CTLA4 and melanoma: Patients with several cancer types, such as melanoma, non-small cell lung cancer, and renal cell carcinoma, have greatly benefited from checkpoint inhibitor therapy, such as anti-PD1 or anti-CTLA-4 (refs. 86–89).